Search Results - "Diergarten, K."

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single-dose Auron Misheil therapy in healthy male subjects by Scheele, J., Diergarten, K., Drevs, J., Niazi, F. R.

“…Summary Background and objective:  Auron Misheil therapy (AMT) is a combination of widely used pharmaceuticals and herbal components that has been used since…”
Get full text

Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer by du Bois, A., Lück, H.-J., Bauknecht, T., Möbus, V., Bochtler, H., Diergarten, K., Meerpohi, H.-G.

“…Purpose: We performed a phase I/II study evaluating the combination of paclitaxel and carboplatin as first-line chemotherapy in patients with advanced ovarian…”
Get full text

Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics by Maier-Lenz, H, Hauns, B, Haering, B, Koetting, J, Mross, K, Unger, C, Bauknecht, T, du Bois, A, Meerpohl, H G, Hollaender, N, Diergarten, K

“…Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most important new drugs used in the treatment of solid tumors. Use of…”
Get more information

Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer by Lück, H J, Thomssen, C, du Bois, A, Untch, M, Lisboa, B, Köhler, G, Diergarten, K

“…Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane used in routine clinical practice, has aroused considerable interest for its…”
Get more information

Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck by Thodtmann, R., Theiss, F., Kemmerich, M., Heinrich, B., Laubenbacher, C., Quasthoff, S., Kau, R., Herzog, M., Diergarten, K., Hanauske, A.-R.

“…Background: Paclitaxel as single agent has shown marked activity in several malignancies. The aim of the present phase II trial was to determine the activity…”
Get full text

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum by du Bois, A., Lück, H.J., Buser, K., Meerpohl, H.G., Sessa, C., Klaassen, U., Meden, H., Bochtler, H., Diergarten, K.

“…An extended phase II study was performed to evaluate single-agent paclitaxel as salvage chemotherapy for ovarian cancer. The aim of this study was to evaluate…”
Get full text

Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer by Havemann, K, Wolf, M, Goerg, C, Faoro, C, Pfab, R, Diergarten, K

“…In a clinical phase II trial, radiotherapy and escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) were given concurrently to…”
Get more information

Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer by Luck, H J, Thomssen, C, duBois, A, Lisboa, B W, Untch, M, Kuhnle, H, Konecny, G, Janicke, F, Meerpohl, H G, Lindner, C, Hecker, D, Diergarten, K

“…Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane to be used routinely in clinical practice, has aroused considerable interest…”
Get more information

Single-agent paclitaxel as a 3-hour infusion by Gatzemeier, U, Neuhauss, R, Schluter, I, von Pawel, J, Wagner, H, Diergarten, K

“…This ongoing phase II trial of patients with inoperable stage IIIB-IV non-small cell lung cancer is seeking to determine the efficacy and toxicity of…”
Get more information

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial by Meerpohl, H G, du Bois, A, Luck, H J, Kühnle, H, Möbus, V, Kreienberg, R, Bauknecht, T, Köchli, O, Bochtler, H, Diergarten, K

“…Recently, a randomized study conducted by the Gynecologic Oncology Group (GOG 111) demonstrated that, given by a 24-hour infusion, the combination of cisplatin…”
Get more information

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single-dose Auron Misheil therapy in healthy male subjects: AMT - safety, tolerability, pharmacokinetics and pharmacodynamics by Scheele, J., Diergarten, K., Drevs, J., Niazi, F. R.

Get full text

Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study by Vogt, H G, Kolotas, C, Martin, T, Schneider, L V, Goes-Schmieder, R, Mitrou, P S, Diergarten, K, Kober, B, Zamboglou, N

“…Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most active single agents for the treatment of non-small cell lung cancer, with…”
Get more information

Simultaneous radiochemotherapy with paclitaxel in non-small cell lung cancer: a clinical phase I study by Vogt, H G, Kolotas, C, Martin, T, Schneider, L V, Neeb, A, Mitrou, P S, Diergarten, K, Dornoff, W, Zamboglou, N

“…Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most active single agents available for the treatment of non-small cell lung…”
Get more information

Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma by Hanauske, A R, Schilling, T, Heinrich, B, Kau, R, Herzog, M, Quasthoff, S, Bochtler, H, Diergarten, K, Rastetter, J

“…We performed a clinical phase I trial of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin in patients with…”
Get more information

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer by Meerpohl, H G, du Bois, A, Kühnle, H, Lück, H J, Kreienberg, R, Möbus, V, Bauknecht, T, Köchli, O, Bochtler, H, Diergarten, K

“…In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in…”
Get more information

Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis by Klaassen, U, Wilke, H, Pari, C P, Strumberg, D, Harstrick, A, Eberhardt, W, Becher, R, Diergarten, K, Seeber, S

“…Phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil/folinic acid (5-FU/FA) in intensively…”
Get more information

Phase II/III study of Auron Misheil Therapy (AMT) versus placebo to evaluate clinical benefit response (CBR) in patients with advanced solid tumors by Drevs, J., Lohrmann, R., Niazi, F., Scheele, J., Diergarten, K.

“…Abstract only e20696 Background: CBR is used as clinical trial endpoint in patients (pts) with advanced cancers. Auron Misheil Therapy (AMT) contains approved…”
Get full text

Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer by Lück, H J, Thomssen, C, du Bois, A, Lisboa, B W, Untch, M, Kühnle, H, Jänicke, F, Meerpohl, H G, Lindner, C, Konecny, G, Hecker, D, Diergarten, K

“…Preliminary results of this ongoing phase II study of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus epirubicin administered as…”
Get more information

Anti-tumor effects of AMT in the renal cell carcinoma model by CABALLERO, Marcello, SCHEELE, Jürgen, ZIRRGIEBEL, Ute, ESSER, Norbert, SCHACHTELE, Christoph, SOLTAU, Jens, RENTSCHLER, Jochen, DIERGARTEN, Klaus, DREVS, Joachim

“…Auron-Misheil-Therapy (AMT) is a defined but unique combination of approved pharmaceuticals. It consists of insulin, chlorpheniramine and an aqueous camomile…”
Get full text

Clinical and pharmacokinetic phase I study with taxol® given as short 1-hour intravenous infusion by Mross, K., Häring, B., Hauns, B., Maier-Lenz, H., Bauknecht, T., Meerpohl, H.G., Diergarten, K., Unger, C.

Get full text